Studybox Research 510(k) Clinical Studies
Bacterial Vaginosis Point-of-Care Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Bacterial vaginosis is the most common cause of vaginal discharge in reproductive-age women, and its reference standards are old: the Amsel clinical criteria at the bedside and the Nugent Gram-stain score in the laboratory. Neither is perfect, the Nugent score includes an intermediate category, and point-of-care tests have been compared to one or both with pre-specified rules for intermediates. The clinical study enrolls symptomatic women, collects the device swab alongside a smear for Nugent scoring and the Amsel components, and reports performance against the chosen reference.
Because the reference depends on trained microscopy readers, central reading of Gram stains with documented inter-reader agreement is a standard element, and Amsel documentation at the visit has to be standardized across sites that may not routinely perform pH or whiff testing. Intended use is typically restricted to symptomatic women, since asymptomatic BV has uncertain clinical significance and the reference performs differently in that population.
- Analyte
- Markers of bacterial vaginosis: sialidase enzyme activity, vaginal pH and amines, or nucleic acid of BV-associated bacteria, depending on the device
- Therapeutic area
- Women's Health
- Specimens
- Vaginal Swab
- Intended-use settings
- physician office, urgent care, emergency department
- Operators
- Clinicians and non-laboratory staff in physician offices and urgent care centers with waived certificates; laboratory staff for moderate-complexity claims.
- Comparator
- Typically Nugent scoring of a Gram-stained vaginal smear by trained readers, with Amsel clinical criteria recorded at the visit; the protocol specifies how intermediate Nugent scores are classified.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- The reference (Nugent, Amsel or a composite) and the rule for intermediate Nugent scores must be pre-specified; results are typically reported against Nugent with intermediates excluded and again with intermediates assigned, so reviewers see both.
- Central Gram stain reading by at least two trained readers with documented agreement is typical, since the reference's own reproducibility affects the device's apparent performance.
- Multiplex vaginitis devices that also report candida or trichomonas have separate references for each, and each is a separate claim.
Endpoints the study must support
- Sensitivity and specificity against Nugent score (and against Amsel criteria where pre-specified), with 95% confidence intervals, in symptomatic women
- Transparent handling of intermediate Nugent scores, with analyses excluding and including them
- Agreement between self-collected and clinician-collected swabs where both are claimed, and invalid rate in waived settings
Enrollment realities
Driven by Nugent-positive symptomatic women, who are a substantial share of women presenting with discharge, so accrual is faster than for most STI tests; intermediate Nugent results and inadequate smears are predictable losses.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
FAQ
Bacterial Vaginosis Point-of-Care Test Study Questions.
01 Who operates the bacterial vaginosis point-of-care test in a 510(k) studies study?
Clinicians and non-laboratory staff in physician offices and urgent care centers with waived certificates; laboratory staff for moderate-complexity claims.
02 What is the comparator for a bacterial vaginosis point-of-care test study?
Typically Nugent scoring of a Gram-stained vaginal smear by trained readers, with Amsel clinical criteria recorded at the visit; the protocol specifies how intermediate Nugent scores are classified.
03 What drives enrollment for a bacterial vaginosis point-of-care test study?
Driven by Nugent-positive symptomatic women, who are a substantial share of women presenting with discharge, so accrual is faster than for most STI tests; intermediate Nugent results and inadequate smears are predictable losses.
Let's talk IVD research
Planning a bacterial vaginosis point-of-care test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.